MedTrace Logo

Peer Social Support During In Vivo Exposure for PTSD

NCT03485391 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2024-08-16

Study results available
· View outcomes & findings →

Summary

Veterans who have prematurely dropped out of exposure therapy for PTSD will be contacted and offered the opportunity to return to treatment, this time with the assistance of an in vivo exposure therapy 'workout buddy'. This peer will meet them at the in vivo exposure therapy location and offer support an encouragement while the patient remains in that location. As the PTSD treatment standards in Charleston and other VA sites across the country increasingly include telemedicine delivered care, both in person and telemedicine based exposure therapy recipients will be included. There will be no randomization; all participants will receive the peer support 'workout buddy' for exposure therapy assignments.

Conditions

  • Stress Disorders, Post-Traumatic
  • Anxiety Disorders
  • Mental Disorder
  • Traumatic Disorder

Interventions

BEHAVIORAL

Prolonged Exposure

Practice guidelines have identified that trauma-focused psychotherapies have most evidence for treatment PTSD. Prolonged Exposure (PE) is one type of trauma-focused psychotherapy. PE teaches you to gradually approach trauma-related memories, feelings, and situations that you have been avoiding since your trauma. By confronting these challenges, you can decrease your PTSD symptoms. Treatment will last anywhere from 8-12 weeks for 75-90 minutes, once per week.

Sponsors & Collaborators

  • Charleston Research Institute

    collaborator OTHER

  • Medical University of South Carolina

    lead OTHER

Principal Investigators

  • Wendy Muzzy, MRA, MLIS · Medical University of South Carolina

  • Ron Acierno, PhD · Ralph H. Johnson VA Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2023-03-03
Completion
2023-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03485391 on ClinicalTrials.gov